Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

September 6, 2023

Immunic to Participate in Industry and Investor Conferences in September
August 17, 2023

Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
August 3, 2023

Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 1, 2023

Immunic to Participate in Investor and Scientific Conferences in August
July 27, 2023

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
June 29, 2023

Immunic to Participate in Scientific and Investor Conferences in July
May 30, 2023

Immunic to Participate in Scientific and Investor Conferences in June
May 17, 2023

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
May 11, 2023

Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 9, 2023

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update

Show per page